LinkedIn·Tuesday, 25 August 2026·1d ago
Two new names now sit on ImmuneWatch's board: Catherine Sanders and Jurgen Del Favero. Catherine ran commercial and business development at…
Tom Bosschaerts
Annotate the epitope specificity of your T-cell receptors | 🔎 ImmuneWatch
Two new names now sit on ImmuneWatch's board: Catherine Sanders and Jurgen Del Favero.
Catherine ran commercial and business development at Adaptive Biotechnologies for years before iOrganBio, where she's Chief Business Officer today.
Jurgen was CTO and co-founder of Multiplicom, and now runs genomics strategy at CellCarta.
That's two decades of turning academic sequencing technology into commercial products people actually pay for. Exactly the gap we needed filled as we scale ImmuneWatch.
Really proud to have them both on board!
♥ 37💬 1↻ 1
View on LinkedIn Cross-referenced
Related on the wire
"We have the PBMCs, is TCR sequencing really worth it?" I am definitely biased but TCR sequencing brings a lot of extra value to the table.…
If you are interested in TCR repertoires analysis, this review by the lab of our academic co-founders is highly recommended! By going over…
'Can you identify and monitor pathogenic T cells in autoimmune diseases?' We get this question more often, so it seems like there is…
New webinar alert! We usually focus on applications in oncology, but we decided to do something different this time and tackle TCR analysis…